Dianthus Therapeutics (NASDAQ:DNTH) Trading 8.4% Higher - What's Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares were up 8.4% during trading on Wednesday . The company traded as high as $19.89 and last traded at $19.79. Approximately 220,548 shares changed hands during trading, a decline of 17% from the average daily volume of 264,374 shares. The stock had previously closed at $18.25.

Wall Street Analyst Weigh In

A number of analysts recently commented on DNTH shares. Robert W. Baird decreased their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Stock Performance

The business has a fifty day moving average price of $18.68 and a 200 day moving average price of $20.36. The company has a market capitalization of $643.20 million, a PE ratio of -6.94 and a beta of 1.38.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently modified their holdings of DNTH. FMR LLC raised its holdings in shares of Dianthus Therapeutics by 0.8% during the 4th quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after buying an additional 36,133 shares during the period. RA Capital Management L.P. raised its holdings in shares of Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after buying an additional 1,000,333 shares during the period. Octagon Capital Advisors LP raised its holdings in shares of Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after buying an additional 231,500 shares during the period. Vestal Point Capital LP raised its holdings in shares of Dianthus Therapeutics by 58.1% during the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company's stock valued at $30,839,000 after buying an additional 625,069 shares during the period. Finally, TCG Crossover Management LLC purchased a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $32,735,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.